Drug Index



Mechanism :

Like GnRH, initial or intermittent administration of nafarelin stimulates release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn transiently increases production of estradiol in females and testosterone in both sexes. However, with continuous daily administration, nafarelin continuously occupies the GnRH receptor, leading to a reversible down-regulation of the GnRH receptors in the pituitary gland and desensitization of the pituitary gonadotropes. This causes a significant and sustained decline in the production of LH and FSH. A decline in gonadotropin production and release causes a dramatic reversible decrease in synthesis of estradiol, progesterone, and testosterone by the ovaries or testes. Like normal endometrium, endometriotic implants contain estrogen receptors. Estrogen stimulates the growth of endometrium. Use of nafarelin induces anovulation and amenorrhea and decreases serum concentrations of estradiol to the postmenopausal range, which induces atrophy of endometriotic implants. However, nafarelin does not abolish the underlying pathophysiology of endometriosis. In children with central precocious puberty receiving nafarelin, serum LH, testosterone, and estradiol concentrations return to prepubertal levels. This results in the suppression of secondary sexual characteristics and decreased rate of linear growth and skeletal maturation. Following discontinuation of nafarelin, the effects of the drug is reversed, meaning FSH and LH concentrations usually return to pre-treatment levels.

Indication :

• For treatment of central precocious puberty (true precocious puberty, GnRH dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.

Contraindications :

Hypersensitivity, Undiagnosed vaginal bleeding, Pregnancy/breast feeding, Caution in PCOS and Osteoporosis, Dyslipidemia.

Dosing :

800 mcg intranasally 2 times daily. Dosage may be increased to 1800 mcg intranasally per day administered as 3 sprays (total of 600 mcg) into alternating nostrils three times a day if adequate suppression not achieved.

Adverse Effect :

For male: Acne, body odour and growth of pubic hair.

For females: Acne, body odour, enlarged breast, growth of pubic hair, emotional liability, seborrhoea, rhinitis, spotting, longer or heavier menstrual periods, breakthrough bleeding.

Interaction :

Levmetamfetamine nasal, Oxymetazoline nasal, Phenylephrine nasal.

Hepatic Dose :

No dosage adjustments are recommended.
08/05/2020 08:52:39 Nafarelin
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0